|View printer-friendly version|
|Nicholas G. Moore Joins Gilead Sciences Board of Directors|
FOSTER CITY, Calif.--(BUSINESS WIRE)--March 25, 2004--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Nicholas G. Moore has been appointed to the company's Board of Directors, bringing the number of Board members to nine.
Mr. Moore, 62, is the recently retired global Chairman of PricewaterhouseCoopers, the firm formed in July 1998 by the merger of Coopers & Lybrand and Price Waterhouse. He was elected Chairman and CEO of Coopers & Lybrand (U.S.) in 1994 and Coopers & Lybrand International in 1997, and served as CEO of the U.S. firm of PricewaterhouseCoopers for two years and for three years as global Chairman of PricewaterhouseCoopers. Mr. Moore presently serves on the Board of Directors of Bechtel Group Inc., Network Appliance Inc., Brocade Communications Systems, Inc., Hudson Highland Group, Inc. and certain private technology companies. He also serves as Chairman of the Board of Trustees of St. Mary's College of California.
Gilead also announced today that Cordell W. Hull, Board member since April 2001, will not stand for re-election to Gilead's Board of Directors at the 2004 Annual Meeting of Stockholders. Mr. Hull will continue in his role as Director through April 2004. James M. Denny, Chairman of Gilead's Board of Directors, will assume Mr. Hull's duties as Chairman of the Board's Audit Committee.
"We are pleased to welcome Nick Moore to the Gilead Board of Directors," said Mr. Denny. "His breadth and depth of experience across a range of industries will greatly benefit Gilead as the company continues to grow its leadership position. I also extend my thanks, on behalf of Gilead and the entire Board, to Cordell Hull for his invaluable service and many contributions over the last three years."
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has six marketed products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
CONTACT: Gilead Sciences, Inc. Susan Hubbard, 650-522-5715 (Investors) Amy Flood, 650-522-5643 (Media) SOURCE: Gilead Sciences, Inc.
Minimum 20 minute delay